About Us

Actinogen Medical  (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influences our personality.

Actinogen Medical’s lead drug candidate, Xanamem, has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s disease, anxiety in Fragile X syndrome, and cognitive impairment in schizophrenia and diabetes

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurodegenerative, psychiatric, and metabolic diseases.

In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy elderly volunteers treated with 20mg Xanamem daily, building on the encouraging data from the earlier XanADu study. The Company plans to initiate a range of Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, schizophrenia, and diabetes.

Our Team

BOARD OF DIRECTORS

DR. GEOFF BROOKE

CHAIRMAN

DR. GEOFF BROOKE

Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years' experience in the healthcare investment industry.
Read More

DR. GEORGE MORSTYN

NON-EXECUTIVE DIRECTOR

DR. GEORGE MORSTYN

Dr Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc.
Read More

MALCOLM McCOMAS

NON-EXECUTIVE DIRECTOR

MALCOLM McCOMAS

Mr. McComas brings 25 years of investment banking experience in M&A, debt and equity funding across multiple industry sectors.
Read More

DR. BILL
KETELBEY

CEO & MANAGING DIRECTOR

DR. BILL KETELBEY

Dr Ketelbey has more than 30 years’ experience in the healthcare, biotech and pharmaceutical industries.
Read More

ACTINOGEN MANAGEMENT

DR. BILL
KETELBEY

CEO & MANAGING DIRECTOR

DR. BILL KETELBEY

Dr Ketelbey has more than 30 years’ experience in the healthcare, biotech and pharmaceutical industries.
Read More

PETER WEBSE

COMPANY
SECRETARY

PETER WEBSE

Mr Webse has over 26 years of company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd.
Read More

JEFF CARTER

CHIEF FINANCIAL
OFFICER

JEFF CARTER

Mr Carter has more than 30 years of expertise in professional accounting, investment banking, corporate finance and commercial / strategic planning roles.
Read More

TAMARA MILLER

VICE PRESIDENT DRUG DEVELOPMENT & STRATEGY

TAMARA MILLER

Tamara joined Actinogen in September 2017, bringing with her over 18 years of international clinical research experience.
Read More

MIRIAM ROESNER

CLINICAL DEVELOPMENT MANAGER

MIRIAM ROESNER

Miriam has over 16 years of experience working in Biotechnology and CRO settings.
Read More

DR. JACK TAYLOR

DRUG DEVELOPMENT SCIENCE LIAISON

JACK TAYLOR

Jack joined Actinogen in February 2020, bringing a deep understanding of pharmaceutical science and a passion for novel drug discovery research.
Read More

THERESE RUSSELL

EXECUTIVE ASSISTANT & OFFICE MANAGER

THERESE RUSSELL

Therese joined the team in 2016, bringing with her over 20 years of experience in administrative and office management.
Read More